PMID- 27330280
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160622
LR  - 20201001
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 10
DP  - 2016
TI  - Mode of administration of dulaglutide: implications for treatment adherence.
PG  - 975-82
LID - 10.2147/PPA.S82866 [doi]
AB  - BACKGROUND: Medication complexity/burden can be associated with nonadherence in 
      patients with type 2 diabetes mellitus (T2DM). Patients' satisfaction with their 
      treatment is an important consideration for physicians. Strategies like using 
      longer acting efficacious agents with less frequent dosing may help adherence. 
      OBJECTIVE: To explore the mode of administration of dulaglutide and its 
      implications for treatment adherence in T2DM. METHODS: PubMed search using the 
      term "Dulaglutide" through October 31, 2015 was conducted. Published articles, 
      press releases, and abstracts presented at national/international meetings were 
      considered. RESULTS/CONCLUSION: Dulaglutide is a once-weekly glucagon like 
      peptide-1 analog with a low intraindividual variability. Phase III trials 
      demonstrated significant improvements in glycemia and weight, with a low 
      hypoglycemia risk similar to liraglutide/exenatide, but with substantially fewer 
      injections. A significant improvement was observed in the total Diabetes 
      Treatment Satisfaction Questionnaire score, Impact of Weight on Self-Perception, 
      and perceived frequency of hyperglycemia with dulaglutide when compared with 
      placebo, exenatide, liraglutide, or metformin. Treatment satisfaction scores 
      showed an improvement with dulaglutide (34%-39%) when compared with exenatide 
      (31%). A positive experience with a high initial (97.2%) and final (99.1%) 
      injection success rate along with a significant reduction in patients' fear of 
      self-injecting, as measured by the modified self-injecting subscale of the 
      Diabetes Fear of Injecting and Self-Testing Questionnaire and Medication Delivery 
      Device Assessment Battery, was found. Its acceptance was high (>96%) among a 
      variety of patients including patients who fear injections and injection-naive 
      users. Dulaglutide is available as a single-dose automatic self-injecting device, 
      which has a low volume, does not need reconstitution, and avoids patient handling 
      of the needle. Dose adjustment based on weight, sex, age, race, ethnicity, or 
      injection-site is not necessary. In chronic diseases like diabetes where patients 
      need lifelong medications, the efficacy, safety, and convenience of a 
      once-weekly, easy-to-use, self-injecting device should encourage patient 
      adherence to dulaglutide therapy.
FAU - Amblee, Ambika
AU  - Amblee A
AD  - Department of Internal Medicine, Division of Endocrinology, John Stroger Hospital 
      of Cook County, Chicago, IL, USA; Rush University Medical Center, Chicago, IL, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160602
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC4898439
OTO - NOTNLM
OT  - patient treatment satisfaction
OT  - quality of life
OT  - treatment satisfaction
OT  - type 2 diabetes
OT  - weekly GLP1
EDAT- 2016/06/23 06:00
MHDA- 2016/06/23 06:01
PMCR- 2016/06/02
CRDT- 2016/06/23 06:00
PHST- 2016/06/23 06:00 [entrez]
PHST- 2016/06/23 06:00 [pubmed]
PHST- 2016/06/23 06:01 [medline]
PHST- 2016/06/02 00:00 [pmc-release]
AID - ppa-10-975 [pii]
AID - 10.2147/PPA.S82866 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2016 Jun 2;10:975-82. doi: 10.2147/PPA.S82866. 
      eCollection 2016.